奥马珠单抗治疗61例慢性自发性荨麻疹的回顾分析  

Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab

作　　者：欧珊珊 陈教全 唐奕 王雪[1,2] 吴伟鸿 邹荟 林天一 李华平 陈荃[2] 朱慧兰[2] OU Shanshan;CHEN Jiaoquan;TANG Yi;WANG Xue;WU Weihong;ZOU Hui;LIN Tianyi;LI Huaping;CHEN Quan;ZHU Huilan(Guangzhou Medical University,Guangzhou 511436,China;Guangzhou Institute of Dermatology,Guangzhou 510095,China;Guangzhou First People's Hospital,Guangzhou 510180,China)

机构地区：[1]广州医科大学,广东广州511436 [2]广州市皮肤病防治所,广东广州510095 [3]广州市第一人民医院,广东广州510180

出　　处：《皮肤性病诊疗学杂志》2023年第2期139-145,共7页Journal of Diagnosis and Therapy on Dermato-venereology

基　　金：广州市临床重大技术项目(2019ZD20)。

摘　　要：目的通过分析真实世界数据,评估奥马珠单抗治疗慢性自发性荨麻疹(CSU)的临床疗效。方法回顾分析2020年9月至2022年11月在广州市皮肤病防治所门诊接受奥马珠单抗治疗3次的61例CSU患者的临床资料。通过7日荨麻疹活动度评分(UAS7)及皮肤病生活质量指数(DLQI)评估疾病严重程度,分析患者使用奥马珠单抗治疗后UAS7及DLQI评分随时间的变化情况;并根据UAS7评分对患者进行分组,对比分析基线临床及实验室资料等在不同疗效和不同反应速度的患者中是否存在差异。结果61例CSU患者均接受12周以上奥马珠单抗治疗。经过治疗,患者UAS7从基线时的28.00(14.00,35.00)分降至第1个月的6.00(0,14.00)分,第3个月达到0(0,4.00)分;DLQI在基线时为8.00(4.00,12.00)分,第1个月降至2.00(0,6.50)分,第3个月达到0(0,2.50)分;第4、8、12周的UAS7评分及DLQI评分与基线相比,差异均有统计学意义(χ^(2)=110.03,P<0.001;χ^(2)=77.02,P<0.001)。59.02%(36/61)患者在使用奥马珠单抗治疗12周后达到完全控制,91.80%(56/61)患者症状得到明显改善。DLQI基线评分在完全反应组与反应欠佳/不反应组的差异有统计学意义(H=-20.74,P=0.042)。结论奥马珠单抗能有效改善CSU症状,提高患者生活质量。Objective To evaluate clinical efficacy of omalizumab in the treatment of chronic spontaneous urticaria(CSU)by analyzing real-world data.Methods We retrospectively analyzed the data of 61 cases with CSU treated with omalizumab for 3 sessions in Guangzhou Institute of Dermatology from September 2020 to November 2022.Urticaria activity score over 7 days(UAS7)and dermatology life quality index(DLQI)score were used to determine the severity of disease.The changes in UAS7 and DLQI scores over the time were analyzed following the treatment with omalizumab.Patients were grouped according to the UAS7 score,and differences in baseline clinical and laboratory data among patients with different efficacy and response rates were compared.Results A total of 61 patients with CSU were treated with omalizumab for 12 weeks.Following the treatment with omalizumab,UAS7 scores decreased from 28.00(14.00,35.00)points at baseline to 6.00(0,14.00)points in the first month,and to 0(0,4.00)points in the third month.Likewise,DLQI scores decreased from 8.00(4.00,12.00)points at baseline to 2.00(0,6.50)points in the first month and to 0(0,2.50)points in the third month.At the end of weeks 4,8,12,UAS7 and DLQI scores were significantly improved compared to the baseline(χ^(2)=110.03,P<0.001;χ^(2)=77.02,P<0.001).After 12-week treatment,symptoms were completely controlled in 59.02%(36/61)of the patients,and markedly improved in 91.80%(56/61)of the patients.The baseline DLQI score in either non-responders or not well-responders was significantly higher than that in well responders(H=-20.74,P=0.042).Conclusion Omalizumab can effectively improve the symptoms and the quality of life of patients with CSU.

关 键 词：慢性自发性荨麻疹 奥马珠单抗 疗效 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]